CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
0.8799
+0.0099 (1.14%)
Oct 16, 2026, 4:00 PM EDT - Market closed
CytoMed Therapeutics Revenue
CytoMed Therapeutics had revenue of 378.88K SGD in the half year ending June 30, 2026, with 69.00% growth. This brings the company's revenue in the last twelve months to 789.04K, up 8.11% year-over-year. In the year 2025, CytoMed Therapeutics had annual revenue of 860.85K with 71.02% growth. That makes CytoMed Therapeutics the 44,293rd largest company in the world by revenue and 6,278th in the United States.
Revenue (ttm)
789.04K SGD
Revenue Growth
+8.11%
P/S Ratio
17.22
Revenue / Employee
18,787 SGD
Employees
42
Market Cap
10.50M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 860.85K | 357.48K | 71.02% |
| Dec 31, 2024 | 503.37K | -4.36K | -0.86% |
| Dec 31, 2023 | 507.74K | 143.82K | 39.52% |
| Dec 31, 2022 | 363.91K | 250.07K | 219.67% |
| Dec 31, 2021 | 113.84K | 54.37K | 91.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
GDTC News
- 9 days ago - Cytomed Therapeutics receives noncompliance notification from Nasdaq - TheFly
- 6 months ago - CytoMed Therapeutics Annual report: H2 2025 - Filings
- 8 months ago - Cytomed Therapeutics refutes ‘misleading’ claims, reaffirms clinical progress - TheFly
- 9 months ago - Cytomed sees ‘enough resources’ to continue activites for ‘at least a year’ - TheFly
- 10 months ago - Cytomed Therapeutics enters into MoU with UMMC - TheFly
- 11 months ago - CytoMed completes acquisition of T cell technology of TC BioPharm - TheFly
- 11 months ago - Cytomed Therapeutics secures investment for subsidiary LongevityBank - TheFly
- 12 months ago - Cytomed Therapeutics chairman Peter Choo increases holdings to 21.95% - TheFly